- CEO
- Toshiyuki Shuto
- Full Time Employees
- 318
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 13-15, Hiyoshi 7-chome Yokohama KN Japan 223-0061
- IPO Date
- Jun 21, 2018
- Business
- Koa Shoji Holdings Co., Ltd. (9273.T) is a Japan-based holding company primarily engaged in the management of subsidiaries focused on the import and sale of active pharmaceutical ingredients (APIs), as well as the manufacture and sale of pharmaceutical products including generic drugs, ethical pharmaceuticals, over-the-counter (OTC) drugs, and health foods; headquartered in Yokohama, Kanagawa, Japan, and established on January 30, 2015. Through its key subsidiaries—Koa Shoji Co., Ltd., which imports and sells generic APIs sourced from over 90 manufacturers in more than 10 countries worldwide and operates a Pharmaceutical Analysis Center for quality assurance and R&D support; Koa Isei Co., Ltd., which manufactures and sells pharmaceuticals mainly consisting of high-potency injections such as anticancer agents, antiemetic agents, pain relievers, agents for pruritic skin diseases, neuropsychiatric agents, agents for metabolic diseases, and anti-rheumatic agents at its facilities in Yamagata including the Zao Factory equipped for vials, syringes, and ampules; and Koa Biotech Bay Co., Ltd., which provides contract packaging of pharmaceutical products, manufactures and sells generic drugs, and markets OTC drugs and health foods—the company operates an integrated business model combining trading and manufacturing to serve generic drug manufacturers, major Japanese pharmaceutical firms, and diverse industry needs with a focus on contract development and manufacturing organization (CDMO) services, stable supply of high-quality low-cost APIs, and self-developed generics targeting cancer, rheumatoid arthritis, and dialysis patients. The group maintains operations primarily in Japan with import networks extending globally, employs 304 people on a consolidated basis as of June 30, 2025, and emphasizes GMP compliance, advanced analytical capabilities, and R&D outsourcing for faster patent expiration items overseas. Recent developments include the 2022 absorption and merger of Koa Pharmaceutical Co., Ltd. by Koa Biotech Bay Co., Ltd., enhancing contract packaging and generic drug production capacities; ongoing expansions such as the 2021 Zao Factory vial production line and Colgate fully automatic ampule packaging operations; and sustained participation in international events like CPHI Frankfurt 2025 and CPHI China 2025 to strengthen global API sourcing and partnerships, alongside a long-term strategy under the "New Business Innovation" slogan to evolve into a specialized API importer and top injectable generic manufacturer potentially via M&A.